Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.82 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.82 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL4285158 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL24202550 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL25403460 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL3121163 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL23690443 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL25403456 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL23549940 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL23690724 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL21907913 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL12377172 | 1.00 | CDK1 (0.82) | CDK1CCNB1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292813-B2 | Iron compositions and methods of making and using the same | RENIBUS THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292813-B2 | Iron compositions and methods of making and using the same | FECH, SLC40A1, TFRC | CDK1 4788/4885CCNB1 4830/4885CA2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.